Intelligence · Patent portfolio
Lxo Ireland Designated Patents
Full USPTO pharma patent portfolio for Lxo Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 201
- Expiring ≤24m
- 3
Quick answer
Lxo Ireland Designated has 201 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 3 expire within 24 months — use filters for patent-cliff planning.
-
US 6140310
Phosphorous prodrugs
expired -
US 6129914
Bispecific antibody effective to treat B-cell lymphoma and cell line
expired -
US 6121256
Compounds activating pharmacological effect of retinoids
expired -
US 6063138
Method and apparatus for the formation of particles
expired -
US 6051432
Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
expired -
US 6051711
Synthesis of swainsonine salts
expired -
US 6048870
3, 5, and/or 6 substituted analogues of swainsonine processes for their preparation and their use as therapeutic agents
expired -
US 6031096
Acyclovir diester derivatives
expired -
US 6013256
Method of preventing acute rejection following solid organ transplantation
expired
Frequently asked questions
How many patents does Lxo Ireland Designated have?
201 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Lxo Ireland Designated patents expire?
3 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory